CHYMEX
LOE Approachingbentiromide
NDAORALSOLUTION
Approved
Dec 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHYMEX (bentiromide) is an oral solution diagnostic agent approved in 1983 for pancreatic function assessment. It is a synthetic peptide substrate that measures chymotrypsin activity in the small intestine to evaluate pancreatic exocrine insufficiency. The drug works by being cleaved by pancreatic enzymes, with metabolites measured in urine to assess pancreatic enzyme output.
LOE Approaching
This product is in late-stage lifecycle with limited commercial growth opportunity; expect smaller team size focused on maintenance rather than expansion activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CHYMEX offers limited career growth due to zero linked job openings and LOE-approaching lifecycle status. This role is best suited for professionals seeking stable, maintenance-focused work in diagnostics or those near career completion, rather than expansion-stage opportunity.
Product ManagerBrand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.